Chloroplasts engineered to express pharmaceutical proteins in edible plants
View Patent ↗Disclosed herein are compositions for conferring oral tolerance in mammals to autoimmune disorders such as diabetes, as well as vectors and methods for plastid transformation of plants to produce a CTB-Pins protein for oral delivery. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to plants edible without torrefying. Exemplified herein is the stable transformation of Lactuca sativa such that CTB-Pins is expressed.
1. A Lactuca sativa homoplasmic plant cell for producing cholera toxin B subunit-proinsulin (CTB-Pins) comprising plastids transformed to express CTB-Pins, said plastids comprising an expression cassette of the following operably linked components, a promoter operative in said plastid, a selectable marker sequence, a psbA 5′ UTR translation element endogenous to Lactuca sativa , a heterologous polynucleotide sequence encoding said proinsulin expressed as a fusion protein conjugated to cholera toxin B subunit (CTB), and a transcription terminator functional in said plastid, said expression cassette being flanked by sequences which are homologous to DNA sequences of the Lactuca sativa plastid and facilitate homologous recombination of said expression cassette into said Lactuca sativa plastid genome in the intergenic region between trnI and trnA genes, said selectable marker sequence encoding an antibiotic-free selectable marker, wherein said plant cell produces a lettuce plant producing cholera toxin B subunit-proinsulin upon propagation.
2. An orally-administrable composition comprising a pharmaceutical protein of interest bioencapsulated in a Lactuca sativa plastid from a homoplasmic lettuce plant cell; said plastid comprising a plastid genome stably transformed with an expression cassette comprising, as operably linked components, a promoter operative in said plastid, a selectable marker sequence, a psbA 5′ UTR translation element endogenous to Lactuca sativa , a heterologous polynucleotide sequence encoding said pharmaceutical protein of interest conjugated to nucleic acid encoding a cholera toxin B subunit, and a transcription terminator functional in said plastid, said expression cassette being flanked by sequences which are homologous to DNA sequences of the Lactuca sativa plastid and facilitate homologous recombination of said expression vector into said Lactuca sativa plastid genome in the intergenic region between trnI and trnA genes, wherein said pharmaceutical protein is proinsulin-CTB which reduces apoptosis in beta cells of the pancreas and increases recruitment of immunosuppressive cytokine producing cells to the pancreas upon oral administration to a subject.
3. A method of retarding the development of or treating diabetes in a subject in need thereof, said method comprising administering to said subject the composition as claimed in claim 2 , said composition further comprising a plant remnant.
4. A stably transformed Lactuca sativa plant which comprises the plant cell of claim 1 or the recombinant progeny of said plant.
5. A method of producing a cholera toxin B subunit-proinsulin containing composition, said method comprising:
obtaining the stably transformed Lactuca sativa plant of claim 4 and
homogenizing material of said stably transformed Lactuca sativa plant to produce homogenized material.
6. The method of claim 5 , further comprising purifying cholera toxin B subunit-proinsulin from said homogenized material.
7. The method of claim 5 , further comprising encapsulating said homogenized material.
8. The method of claim 7 , wherein said homogenized material is not cooked prior to encapsulation.
9. The method of claim 5 , wherein said homogenized material is dried to produce a powder.
10. The method of claim 9 , further comprising encapsulating said powder.